Avanafil

Avanafil is a PDE5 inhibitor approved for erectile dysfunction by the FDA on April 27, 2012[1] and by EMA on June 21, 2013.[2] Avanafil is known by the trademark names Stendra and Spedra. It was invented at Mitsubishi Tanabe Pharma, formerly known as Tanabe Seiyaku Co.,[3] and licensed to Vivus Inc., which partnered with Menarini Group to commercialise Spedra in over forty European countries, Australia, and New Zealand.[4] Metuchen Pharmaceuticals obtained exclusive rights within the United States.[5]

Avanafil
Avanafil is a PDE5 inhibitor
Clinical data
Trade namesStendra
License data
Pregnancy
category
  • US: C (Risk not ruled out)
    Routes of
    administration    		Oral
    ATC code
    Legal status
    Legal status
    Identifiers
    CAS Number
    PubChem CID
    IUPHAR/BPS
    ChemSpider
    UNII
    KEGG
    ChEMBL
    CompTox Dashboard (EPA)
    Chemical and physical data
    FormulaC23H26ClN7O3
    Molar mass483.951 g/mol g·mol−1
    3D model (JSmol)
     NY (what is this?)  (verify)

    Avanafil acts by inhibiting a specific phosphodiesterase type 5 enzyme found in various body tissues, primarily in the corpus cavernosum penis.[6] Other similar drugs are sildenafil, tadalafil and vardenafil. The advantage of avanafil is that it has very fast onset of action compared with other PDE5 inhibitors. It is absorbed quickly, reaching a maximum serum concentration in about thirty to forty-five minutes.[7] About two-thirds of the participants were able to engage in sexual activity within fifteen minutes.[7]

    Synthesis

    Avanafil can be synthesized from a benzylamine derivative and a pyrimidine derivative:[8]

    See also

    References
    1. "FDA approves Stendra for erectile dysfunction" (Press release). Food and Drug Administration (FDA). April 27, 2012.
    2. "Spedra (avanafil)". European Medicines Agency. Retrieved 17 April 2014.
    3. https://patents.google.com/patent/US6656935B2
    4. "Archived copy". Archived from the original on 2015-12-08. Retrieved 2013-07-26.CS1 maint: archived copy as title (link)
    5. http://ir.vivus.com/news-releases/news-release-details/vivus-and-metuchen-pharmaceuticals-announce-license-agreement
    6. "avanafil, Spedra". Medicine Net. Retrieved 17 April 2014.
    7. Kyle, Jeffery; Brown, Dana (2013). "Avanafil for Erectile Dysfunction" (PDF). Annals of Pharmacotherapy. Sage Publishing. doi:10.1177/1060028013501989. Retrieved 28 September 2013.
    8. Yamada, K.; Matsuki, K.; Omori, K.; Kikkawa, K.; 2004, U.S. Patent 6,797,709
    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.